Full metadata record
DC FieldValueLanguage
dc.contributor.authorRusso, Patrizia-
dc.contributor.authorDel Bufalo, Alessandra-
dc.contributor.authorFini, Massimo-
dc.date.accessioned2015-04-22T12:41:19Z-
dc.date.available2015-04-22T12:41:19Z-
dc.date.issued2015-02-10-
dc.identifier.issn1611-2156-
dc.identifier.urihttp://hdl.handle.net/2003/34057-
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-7879-
dc.description.abstractThe deep-sea habitat is a source of very potent marine-derived agents that may inhibit the growth of human cancer cells “in vitro” and “in vivo”. Salinosporamide-A, Marizomib, by Salinispora species is a proteasome inhibitor with promising anticancer activity (Phase I/II trials). Different deep-sea-derived drugs are under preclinical evaluation. Cancer is a complex disease that may be represented by network medicine. A simple consequence is the change of the concept of target entity from a single protein to a whole molecular pathway and or cellular network. Deep-sea-derived drugs fit well to this new concept.en
dc.language.isoen-
dc.relation.ispartofseriesEXCLI Journal ; Vol. 14, 2015en
dc.subjectdeep-sea-derived drugsen
dc.subjectcanceren
dc.subjectsystems medicineen
dc.subjectnetworken
dc.subjecttherapyen
dc.subjectpreclinical studiesen
dc.subjectclinical studiesen
dc.subject.ddc610-
dc.titleDeep sea as a source of novel-anticancer drugsen
dc.title.alternativeUpdate on discovery and preclinical/clinical evaluation in a systems medicine perspectiveen
dc.typeText-
dc.type.publicationtypearticle-
dcterms.accessRightsopen access-
eldorado.dnb.zdberstkatid2132560-1-
Appears in Collections:Review Articles

Files in This Item:
File Description SizeFormat 
Russo_10022015_proof.pdfDNB141.79 kBAdobe PDFView/Open


This item is protected by original copyright



This item is protected by original copyright rightsstatements.org